CJC-1295 + Ipamorelin
10 mg · Lyophilized powder
Sold out
Research blend: CJC-1295 (no DAC) 5 mg + ipamorelin 5 mg.
Need larger quantities? Wholesale pricing for qualified businesses
For laboratory research use only by qualified researchers. Not for human or veterinary use. Not a drug, dietary supplement, cosmetic or food. Not evaluated by the FDA for any use.
Quick Summary
Investigational components — blend not studiedA blend of two separately studied peptides that act on different growth hormone signals: CJC-1295 without DAC, a modified GHRH(1-29) analogue, and ipamorelin, a ghrelin-receptor agonist. Ipamorelin reached phase 2 trials but was never approved, and published human data for CJC-1295 come from its albumin-binding DAC version. No study of this combination was identified.
Areas of research
- Growth hormone release
- Postoperative ileus
- Long-acting GHRH analogues
- Anti-doping science
- Amount
- 10 mg
- Form
- Lyophilized powder
- References
- 6 cited
- COA
- Batch report pending
- Free U.S. shipping on orders of $150 or more
- Lyophilized powder in a sealed vial
Research Use Notice. This product is intended for laboratory and research purposes. It is not intended for human consumption or personal medical use. Product information is provided for scientific and educational context only. See our Research Use Policy.
Why Researchers Study It
- Combining a GHRH-receptor signal with a ghrelin-receptor signal, a question not tested for this blend
- Selective growth hormone release by ipamorelin in animal studies
- Growth hormone pulse patterns during sustained GHRH-receptor stimulation (studied with CJC-1295 with DAC)
- Detection by anti-doping laboratories, since both are named on WADA's list
What It Is
This vial combines two synthetic peptides in equal amounts: CJC-1295 without DAC and ipamorelin.
This vial combines two synthetic peptides in equal amounts: CJC-1295 without DAC and ipamorelin. Each has its own research history, and they were studied separately.
CJC-1295 without DAC is a GHRH(1-29) amide with four amino acid substitutions, designed to act like growth hormone-releasing hormone at the pituitary. It lacks the albumin-binding linker (DAC) of the CJC-1295 drug tested in published human studies.
Ipamorelin is a five-amino-acid peptide developed at Novo Nordisk that activates the ghrelin receptor (GHS-R1a). In rat and pig studies it released growth hormone without raising ACTH or cortisol.
Because the two act on different receptors that both lead to growth hormone release, they are often grouped together. No published study of this pair or this ratio was identified.
How It Works
3 established · 2 proposed or under investigation
Established
- Ipamorelin activates the ghrelin receptor in the pituitary, releasing growth hormone in rat cells, rats and pigs
- CJC-1295 is a GHRH(1-29) analogue designed to act at the GHRH receptor; its human data come from the albumin-bound DAC version
- No mechanism has been established for the combination
Proposed / under investigation
- Acting on two receptors at once might produce a larger growth hormone response than either alone; this has not been tested for this blend
- Without DAC, CJC-1295 is expected to act for a much shorter time than the DAC version; this is not well measured
Research Status & Evidence
Investigational components — blend not studied
Ipamorelin's phase 2 trial found no difference from placebo, and human CJC-1295 studies used the DAC version. Neither peptide is approved.
Types of evidence
- Available: Cell & lab studies
- Available: Animal studies
- Available: Early human studies
- Available: Clinical trials
- Not available: Approved medical use
The evidence belongs to the separate components. Ipamorelin's selectivity data come from rat and pig studies, and its main human trial, a phase 2 study in bowel-surgery patients, found no significant difference from placebo. Human CJC-1295 data come from small 2006 studies of the DAC version. No study of the combination was identified.
Areas of research
- Growth hormone releaseGHRH and ghrelin receptor pharmacology
- Postoperative ileusipamorelin phase 2 trial (negative)
- Long-acting GHRH analogueshuman studies of CJC-1295 with DAC
- Anti-doping scienceboth components on WADA's prohibited list
Limitations
- No published study has examined this combination or ratio
- Neither peptide is approved by the FDA or any other regulator
- Results for CJC-1295 with DAC should not be assumed for the no-DAC peptide in this blend
- FDA lists ipamorelin acetate in 503B Category 2 of its compounding safety-risk list; CJC-1295 appears there among withdrawn nominations, with FDA citing serious adverse events including increased heart rate
- Both are prohibited at all times in sport under the WADA 2026 Prohibited List
Specifications
10 mg · Lyophilized powder
- Product
- CJC-1295 + Ipamorelin
- Category
- Blends
- Size
- 10 mg
- Form
- Lyophilized powder
- Synonyms
- CJC-1295 / Ipamorelin blend; Mod GRF 1-29 + Ipamorelin; Modified GRF (1-29) and ipamorelin
- SKU
- REN-CJCIPA-10
Testing & COA Batch report pending
Research References (6)
Linked sources · last reviewed October 2026
- Raun K et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol 1998 · PubMed 9849822
- Beck DE et al. Proof-of-concept study of the ghrelin mimetic ipamorelin for postoperative ileus in bowel resection patients. Int J Colorectal Dis 2014 · PubMed 25331030
- Teichman SL et al. Prolonged stimulation of GH and IGF-I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab 2006 · PubMed 16352683
- Ionescu M, Frohman LA. Pulsatile secretion of GH persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab 2006 · PubMed 17018654
- FDA. Certain bulk drug substances for use in compounding that may present significant safety risks (updated April 2026) · fda.gov
- WADA. The 2026 Prohibited List, section S2.2.4 (copy published by JADCO) · jadco.gov.jm
Summaries are written by Renuvia Labs from the sources above for educational context only. Last reviewed October 30, 2026.
Frequently Asked Questions
What is in the CJC-1295 + Ipamorelin vial?
Two peptides in equal amounts: 5 mg of CJC-1295 without DAC (also sold as modified GRF 1-29) and 5 mg of ipamorelin, in one 10 mg lyophilized vial.
Has the CJC-1295 and ipamorelin combination been studied?
Not as a combination. Each peptide has its own research history and they were studied separately. Ipamorelin's phase 2 trial found no difference from placebo, and the published human CJC-1295 studies used the DAC version, a different molecule. Neither peptide is approved.
When will CJC-1295 + Ipamorelin be available?
CJC-1295 + Ipamorelin is sold out right now. Use "Email me when it's available" on this page and we send one email when it is back in stock. Every lot is listed in the COA library with its Certificate of Analysis once the lab issues it.
What size is the CJC-1295 + Ipamorelin vial?
The blend is supplied as a single 10 mg lyophilized vial: 5 mg CJC-1295 (no DAC) and 5 mg ipamorelin.
What is CJC-1295 + Ipamorelin?
A blend of two separately studied peptides that act on different growth hormone signals: CJC-1295 without DAC, a modified GHRH(1-29) analogue, and ipamorelin, a ghrelin-receptor agonist. Ipamorelin reached phase 2 trials but was never approved, and published human data for CJC-1295 come from its albumin-binding DAC version. No study of this combination was identified.
Is there a CJC-1295 + Ipamorelin coupon or discount code?
There is no public coupon code. New customers get a first-order discount for joining the Renuvia email list, volume pricing starts at 2 vials of CJC-1295 + Ipamorelin, and U.S. shipping is free over $150. Codes on third-party coupon sites are not valid here.
What are other names for CJC-1295 + Ipamorelin?
CJC-1295 + Ipamorelin is also referred to as CJC-1295 / Ipamorelin blend, Mod GRF 1-29 + Ipamorelin, Modified GRF (1-29) and ipamorelin.
What sizes is Renuvia Labs CJC-1295 + Ipamorelin available in?
CJC-1295 + Ipamorelin is listed in 10 mg, supplied as lyophilized powder in a sealed glass vial. It is sold for laboratory research use only.
Where is the Certificate of Analysis for CJC-1295 + Ipamorelin?
Certificates of Analysis are published per lot in the Renuvia Labs COA library, searchable by product, SKU or lot number. CJC-1295 + Ipamorelin shows "pending" there until the current lot's report exists; it is then linked on this page too.
Is this in stock?
Yes, unless the page says sold out. You reserve it with no payment today, and we email payment instructions in approximately 1–2 business days. Your order ships once payment arrives.
What form is this product supplied in?
Peptides and research compounds ship as lyophilized (freeze-dried) powder in a sealed glass vial. The fill amount printed on the product page and label is the total content of the vial.
Is this product for human use?
No. All Renuvia Labs products are sold strictly for laboratory research use. They are not for human or animal consumption and are not intended to diagnose, treat, cure or prevent any disease.
Do you offer volume pricing?
Yes. Per-vial pricing drops automatically at 2, 3 and 5 vials of the same product; the current tiers are shown next to the price. For larger quantities, see our wholesale program.
How much is shipping?
Free U.S. shipping on orders of $150 or more; $8.95 flat rate below that.
Do you ship outside the U.S.?
No. Renuvia Labs ships to U.S. addresses only. Research institutions outside the U.S. can enquire through the wholesale program.
